Phase IV, single arm study to obtain information regarding the safety and efficacy of fondaparinux given outpatient for treatment of acute pulmonary embolism

Trial Profile

Phase IV, single arm study to obtain information regarding the safety and efficacy of fondaparinux given outpatient for treatment of acute pulmonary embolism

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Warfarin
  • Indications Pulmonary embolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2017 Status changed to withdrawn prior to enrolment as enrollment criteria not met by PI patient population
    • 08 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top